TuHURA Biosciences (NASDAQ:HURA) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of TuHURA Biosciences (NASDAQ:HURA) in a research report released on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $13.00 price objective on the stock.

A number of other research firms have also recently commented on HURA. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. Maxim Group initiated coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They set a “buy” rating and a $15.00 target price for the company. Finally, RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th.

TuHURA Biosciences Price Performance

HURA stock opened at $2.11 on Monday. The stock’s 50-day moving average is $4.13. TuHURA Biosciences has a 52 week low of $1.89 and a 52 week high of $14.60.

Institutional Trading of TuHURA Biosciences

Several large investors have recently bought and sold shares of HURA. Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences during the 4th quarter valued at about $253,000. Suncoast Equity Management purchased a new stake in TuHURA Biosciences during the 4th quarter valued at about $421,000. Charles Schwab Investment Management Inc. purchased a new stake in TuHURA Biosciences during the 4th quarter valued at about $61,000. Accent Capital Management LLC purchased a new stake in TuHURA Biosciences during the 4th quarter valued at about $29,000. Finally, Geode Capital Management LLC purchased a new stake in TuHURA Biosciences during the 4th quarter valued at about $1,084,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.